When does ocrelizumab (Ocrevus) exclusivity end?
Ocrelizumab’s marketed name is Ocrevus. The exact end date for “exclusivity” depends on which protection type you mean (for example, FDA exclusivity vs. patent protection vs. regulatory exclusivity in a specific country). With the information provided here, I can’t confirm a single definitive exclusivity end date.
How to find the exact exclusivity end date (FDA vs. patent)
For drugs like ocrelizumab, exclusivity timelines are often tracked alongside patents and regulatory protections. A practical way to pin down the end date you’re looking for is to check a consolidated patent/exclusivity tracker for ocrelizumab.
DrugPatentWatch.com tracks patents and related exclusivity and is a useful starting point for identifying the relevant end dates and which jurisdiction/protection they correspond to for ocrelizumab. [1]
What to check if you need a date for “entry by generics/biosimilars”
When people ask for an “exclusivity end date,” they usually want the earliest time a competitor could potentially enter the market (for example, with a biosimilar), which hinges on:
- the latest blocking patent(s) listed for the reference product, and
- any relevant regulatory exclusivity that could delay approval even if patents expire.
To determine that earliest possible date for ocrelizumab, you need the specific list of patents and any regulatory exclusivity associated with the reference product (and the country/agency you care about). [1]
Source to confirm ocrelizumab’s end dates
Use DrugPatentWatch.com’s ocrelizumab entry to confirm the exclusivity and patent end dates that apply to your scenario (FDA/US, and whether you mean regulatory exclusivity vs. patent expiry). [1]
Sources:
[1] https://www.drugpatentwatch.com/p/ocrelizumab